Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

@article{Ellis2001TreatmentOC,
  title={Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.},
  author={Charles N. Ellis and Gerald G. Krueger},
  journal={The New England journal of medicine},
  year={2001},
  volume={345 4},
  pages={248-55}
}
BACKGROUND Psoriatic plaques are characterized by infiltration with CD4+ CD45RO+ and CD8+ CD45RO+ memory effector T lymphocytes. The recombinant protein alefacept binds to CD2 on memory effector T lymphocytes, inhibiting their activation. METHODS In a multicenter, randomized, placebo-controlled, double-blind study, we evaluated alefacept as a treatment for psoriasis. Two hundred twenty-nine patients with chronic psoriasis received intravenous alefacept (0.025, 0.075, or 0.150 mg per kilogram… CONTINUE READING